Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2026-01-25 @ 8:17 AM
Study NCT ID:
NCT03062358
Status:
COMPLETED
Last Update Posted:
2025-09-30
First Post:
2017-02-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-04-27
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-10-15
Completion Date Type:
ACTUAL
First Submit Date:
2017-02-21
First Submit QC Date:
None
Study First Post Date:
2017-02-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-06-07
Results First Submit QC Date:
None
Results First Post Date:
2023-03-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-11
Last Update Post Date:
2025-09-30
Last Update Post Date Type:
ESTIMATED